CTLA4 and glioblastoma: Recent investigations specifically focusing on GBM with epidermal growth factor receptor variant III (EGFRvIII) mutations have uncovered an increasing abundance of PMN-MDSCs, correlating with resistance to PD-1 and CTLA-4 inhibitors.